Business

Director Dealings

Director Dealings.

articleOxford Biomedica PlcSeptember 20, 20235/company/oxford-biomedica-plc/news/director-dealings-52
Director Dealings

About this update from Oxford Biomedica Plc

[{"type":"text","content":"\n\n \n \nDirector Dealings\n \nOxford, UK - 20 September 2023: Oxford Biomedica plc (LSE:OXB) (\"Oxford Biomedica\" or \"the Company\"), a quality and innovation-led cell and gene therapy CDMO, today announces the following share purchases by certain Directors and Senior management.  \n \n \n\n\n\nName of PDMR\n\n\nNumber of ordinary shares purchased\n\n\nNumber of ordinary shares now held\n\n\nTotal number of ordinary shares held as a percentage of the Company's share capital\n\n\n\n\nDr. Roch Doliveux\n\n\n36,130\n\n\n371,805\n\n\n0.385%\n\n\n\n\nDr. Frank Mathias\n\n\n20,000\n\n\n20,000\n\n\n0.020%\n\n\n\n\nStuart Paynter\n\n\n4,030\n\n\n18,687\n\n\n0.019%\n\n\n\n\nLeone Patterson\n\n\n5,849\n\n\n5,849\n\n\n0.0061%\n\n\n\n\nCatherine Moukheibir\n\n\n7,226\n\n\n25,756\n\n\n0.027%\n\n\n\n\nStuart Henderson\n\n\n1,000\n\n\n10,862\n\n\n0.011%\n\n\n\n\nSebastien Ribault*\n\n\n1,500\n\n\n-\n\n\n-\n\n\n\n\nNick Page*\n\n\n11,678\n\n\n-\n\n\n-\n\n\n\n\nMatthew Treagus*\n\n\n3,842\n\n\n-\n\n\n-\n\n\n\n\nJames Miskin*\n\n\n1,808\n\n\n-\n\n\n-\n\n\n\n*Senior Management\n \nThe below notifications, made in accordance with the requirements of the EU Market Abuse Regulation, give further details of the number of ordinary shares purchased.\n \n\n\n\n1.\n\n\nDetails of the Person Discharging Managerial Responsibility (\"PDMR\")\n\n\n\n\na)\n\n\nName\n\n\nDr. Roch Doliveux\n\n\n\n\n2.\n\n\nReason for the notification\n\n\n\n\na)\n\n\nPosition/status\n\n\nNon-Executive Chairman\n \n\n\n\n\nb)\n\n\nInitial notification/\namendment\n\n\nInitial Notification\n\n\n\n\n3.\n\n\nDetails of the Issuer\n\n\n\n\na)\n\n\nName\n\n\nOxford Biomedica plc\n\n\n\n\nb)\n\n\nLEI code\n\n\n213800S1GVQNXQ15K851\n\n\n\n\n4.\n\n\nDetails of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted\n\n\n\n\na)\n\n\nDescription of the financial instrument\n \nIdentification code\n\n\nOrdinary Shares of 50 pence each\n \n \nISIN: GB00BDFBVT43\n\n\n\n\nb)\n\n\nNature of the transaction\n\n\nPurchase of shares  \n\n\n\n\nc)\n\n\nCurrency\n\n\nGBP - British pound\n\n\n\n\nd)\n\n\nPrice(s) and volumes(s)\n \n \n \n \n\n\n \n\n\n\nPrice(s)\n\n\nVolume...

More updates from Oxford Biomedica Plc